Abstract
In the first arm, the COMPASS study compared the efficacy of rivaroxaban, the combination of rivaroxaban with acetylsalicylic acid (ecASA) and ecASA alone in the indication of vascular prophylaxis in patients with ischemic heart disease or peripheral vascular disease. The second arm evaluated whether the addition of proton pump inhibitors (IPP) lowers the rate of gastrointestinal events, especially bleeding from the higher part of the digestive tract.
The study confirmed that co-medication with IPP during antithrombotic therapy with direct anticoagulant - rivaroxaban, ecASA or their combination - administered in the context of secondary prevention of atherothrombotic events did not decrease the rate of hemorrhagic events in the gastrointestinal tract.